XML 150 R77.htm IDEA: XBRL DOCUMENT
v3.22.4

Segmentation of key figures - Net sales by region (Details 7) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 50,545 | $ 51,626 | $ 48,659
Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 6.00% |
Europe [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 18,467 | $ 20,197 | 18,715
Europe [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (9.00%) | 8.00% |
US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 17,653 | $ 16,818 | 16,484
US | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 5.00% | 2.00% |
Asia/Africa/Australasia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 10,542 | $ 10,966 | 10,219
Asia/Africa/Australasia [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (4.00%) | 7.00% |
Canada and Latin America [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 3,883 | $ 3,645 | 3,241
Canada and Latin America [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 7.00% | 12.00% |
Established Markets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 37,008 | $ 38,314 | 36,732
Established Markets [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (3.00%) | 4.00% |
Emerging Growth Markets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 13,537 | $ 13,312 | 11,927
Emerging Growth Markets [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 2.00% | 12.00% |
Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 41,296 | $ 41,995 | 39,013
Innovative Medicines | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 8.00% |
Innovative Medicines | Europe [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 13,554 | $ 14,919 | 13,484
Innovative Medicines | Europe [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (9.00%) | 11.00% |
Innovative Medicines | US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 15,899 | $ 14,999 | 14,342
Innovative Medicines | US | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 6.00% | 5.00% |
Innovative Medicines | Asia/Africa/Australasia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 8,929 | $ 9,304 | 8,718
Innovative Medicines | Asia/Africa/Australasia [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (4.00%) | 7.00% |
Innovative Medicines | Canada and Latin America [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 2,914 | $ 2,773 | 2,469
Innovative Medicines | Canada and Latin America [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 5.00% | 12.00% |
Innovative Medicines | Established Markets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 30,548 | $ 31,459 | 29,643
Innovative Medicines | Established Markets [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (3.00%) | 6.00% |
Innovative Medicines | Emerging Growth Markets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 10,748 | $ 10,536 | 9,370
Innovative Medicines | Emerging Growth Markets [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 2.00% | 12.00% |
Sandoz |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 9,249 | $ 9,631 | 9,646
Net sales, change in % | (4.00%) | 0.00% |
Sandoz | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (4.00%) | 0.00% |
Sandoz | Europe [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 4,913 | $ 5,278 | 5,231
Sandoz | Europe [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (7.00%) | 1.00% |
Sandoz | US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,754 | $ 1,819 | 2,142
Sandoz | US | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (4.00%) | (15.00%) |
Sandoz | Asia/Africa/Australasia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,613 | $ 1,662 | 1,501
Sandoz | Asia/Africa/Australasia [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (3.00%) | 11.00% |
Sandoz | Canada and Latin America [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 969 | $ 872 | 772
Sandoz | Canada and Latin America [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 11.00% | 13.00% |
Sandoz | Established Markets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 6,460 | $ 6,855 | 7,089
Sandoz | Established Markets [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (6.00%) | (3.00%) |
Sandoz | Emerging Growth Markets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 2,789 | $ 2,776 | $ 2,557
Sandoz | Emerging Growth Markets [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 0.00% | 9.00% |
Operating segments [member] | Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 8.00% |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |